Pathophysiological Aspects of Lipoprotein-Associated Phospholipase A2: A Brief Overview
- 22 February 2014
- book chapter
- Published by Springer Nature
- p. 115-133
Abstract
No abstract availableKeywords
This publication has 111 references indexed in Scilit:
- Translational Studies of Lipoprotein-Associated Phospholipase A2 in Inflammation and AtherosclerosisJACC, 2012
- Association of Pulse Pressure, Arterial Elasticity, and Endothelial Function With Kidney Function Decline Among Adults With Estimated GFR >60 mL/min/1.73 m2: The Multi-Ethnic Study of Atherosclerosis (MESA)American Journal of Kidney Diseases, 2012
- Kidney Function Decline in the Elderly: Impact of Lipoprotein-Associated Phospholipase A2American Journal of Nephrology, 2011
- Lipoprotein-Associated Phospholipase A 2 Activity Predicts Progression of Subclinical Coronary AtherosclerosisDiabetes Technology & Therapeutics, 2011
- Lipoprotein-associated phospholipase A2 and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health StudyDiabetologia, 2010
- Association of Lp-PLA2 activity with allele-specific Lp(a) levels in a bi-ethnic populationAtherosclerosis, 2010
- Lipoprotein-associated phospholipase A2 (Lp-PLA2) and risk of cardiovascular disease in older adults: Results from the Cardiovascular Health StudyAtherosclerosis, 2009
- Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcomeEuropean Heart Journal, 2009
- Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque developmentNature Medicine, 2008
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005